Lesinurad , 98% , 878672-00-5
CAS NO.：878672-00-5
Empirical Formula: C17H14BrN3O2S
Molecular Weight: 404.28
MDL number:
EINECS: 689-245-8
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB199.20 | In Stock |
|
| 10MG | RMB319.20 | In Stock |
|
| 25mg | RMB639.20 | In Stock |
|
| 50MG | RMB999.20 | In Stock |
|
| 100mg | RMB1599.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >171oC (dec.) |
| Boiling point: | 643.7±65.0 °C(Predicted) |
| Density | 1.72±0.1 g/cm3(Predicted) |
| storage temp. | -20°C Freezer, Under inert atmosphere |
| solubility | DMSO (Slightly), Methanol (Slightly, Heated) |
| pka | 2.91±0.10(Predicted) |
| form | Solid |
| color | White to Off-White |
Description and Uses
Approved by the FDA late in 2015, lesinurad is an urate anion exchange transporter 1 (URAT1) inhibitor for use in the treatment of gout. Ardea Biosciences, which is a subsidiary of AstraZeneca, developed lesinurad to be used in a combination therapy with xanthine oxidase inhibitors for the treatment of hyperuricaemia associated with gout. The approval process is ongoing in several other countries across the globe, with the EMA Committee for Medicinal Products for Human Use giving lesinurad a positive opinion for use as an adjunctive therapy in combination with xanthine oxidase inhibitors to treat hyperuricaemia.
Lesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
